论文部分内容阅读
目的乳腺癌是女性最常见的恶性肿瘤之一,并且是女性癌症死亡的首要原因。本研究总结肝X受体(liver X receptor,LXR)及其激动剂的特征和它们在乳腺癌中的研究进展,探索LXR作用于乳腺癌的靶基因,为乳腺癌的靶向治疗寻找新靶点提供思路。方法通过查阅PubMed和CNKI数据库,以“肝X受体、乳腺癌、肿瘤、ABCA1和ABCG1”为关键词,检索2010-01-2016-01相关文献,共检索到英文文献249条,中文文献176条。纳入标准:肝X受体的特性;肝X受体在不同肿瘤中的机制研究;肝X受体与乳腺癌的相关性。排除标准:未涉及肝X受体及其靶基因的乳腺癌和其他肿瘤的研究。根据纳入标准,符合分析文献29篇,并加入原始文献3篇。结果 LXR激动剂对多种癌细胞均有抑制作用,但其内源性激动剂27HC在ER阳性乳腺癌中也可激活ER促进乳腺癌细胞增殖。LXR通过其靶基因三磷酸腺苷结合盒转运体A1(ATP binding cassette transporter A1,ABCA1)或三磷酸腺苷结合盒转运体G1(ATP binding cassette transporter G1,ABCG1)介导胆固醇代谢参与乳腺癌的发病机制。结论 LXR激动剂具有双向调节乳腺癌细胞的作用。LXR是通过ABCA1还是ABCG1参与乳腺癌的发病机制,目前尚存在争议。
Purpose Breast cancer is one of the most common malignancies in women and is the leading cause of cancer death in women. This study summarizes the characteristics of liver X receptor (LXR) and its agonists and their progress in breast cancer and explores the role of LXR in breast cancer target genes and find new targets for the targeted therapy of breast cancer Point to provide ideas. Methods The databases of PubMed and CNKI were searched, and the key words of “liver X receptor, breast cancer, tumor, ABCA1 and ABCG1” were searched. A total of 249 articles were retrieved from English, Article 176. Inclusion criteria: Characteristics of liver X receptors; Mechanisms of liver X receptors in different tumors; Correlation between liver X receptors and breast cancer. Exclusion criteria: Study of breast and other tumors that do not involve liver X receptors and their target genes. According to the inclusion criteria, 29 articles were analyzed and 3 articles were added to the original documents. Results LXR agonists could inhibit a variety of cancer cells, but 27HC, an endogenous agonist, could also activate ER in ER-positive breast cancer to promote the proliferation of breast cancer cells. LXR is involved in the pathogenesis of breast cancer through its target gene ATP binding cassette transporter A1 (ABCA1) or ATP binding cassette transporter G1 (ABCG1). Conclusion LXR agonists have the effect of regulating breast cancer cells in both directions. Whether LXR is involved in the pathogenesis of breast cancer through ABCA1 or ABCG1 remains controversial.